Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 1115-1119

  Christensen, Peer Brehm ^a   Krarup, Henrik Bygum ^b   Laursen, Alex Lund ^c   Madsen, Poul Henning ^b   Pedersen, Court ^a   Schlichting, Poul ^d   Orholm, Marianne ^e   Ring Larsen, Helmer ^d   Bukh, Jens ^f,g   Krogsgaard, Kim ^f  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Elsinore Hospital   (Denmark)

^f Mental Health Services CPH   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Hepatitis C; Pegylated interferon alfa 2a; Ribavirin concentration; Treatment; Viral kinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MICROBIAL KINETICS; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PREDICTIVE VALUE; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865789247     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.694905     Document Type: Article

References (12)

1. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364: 1195-206.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364: 2405-16.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461: 399-401.
4. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46: 78-84.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347: 975-82.
6. Krarup HB, Drewes AM, Madsen PH. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998;58: 415-22.
7. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: 798-801.
8. Hansen N, Obel N, Christensen PB, Kjaer M, Laursen AL, Krarup HB, et al. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011;11: 177.
9. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-55.
10. Dienstag JL, McHutchison JG. American Gastroentero-logical Association technical review on the management of hepatitis C. Gastroenterology 2006;130: 231-64.
11. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47: 1837-45.
12. Feld J, Lucthman G, Loomba R, Modi A, Rotman Y, Nagabhyru P, et al. Twice vs once weekly dosing of pegin-terferon alfa 2a in chronic HCV genotype 1 infection: analysis of early viral kinetics. Hepatology 2007;46: 343A.